Sustained release microneedle patch for pronounced systemic delivery of doxazosin mesylate
![Sustained release microneedle patch for pronounced systemic delivery of doxazosin mesylate](https://www.pharmaexcipients.com/wp-content/uploads/2024/08/Sustained-release-microneedle-patch-for-pronounced-systemic-delivery-of-doxazosin-mesylate.jpg)
Abstract
Introduction: Microneedle patch is one of the fascinating drug delivery approaches that offers low invasiveness and a painless physical application to enhance the delivery of micro and macro-molecules into the skin.
Methods: Variable contents of chitosan and polyvinyl alcohol were used for the development of doxazosin mesylate containing sustained release microneedle patches via solvent casting technique. The prepared patches were evaluated for microscopic evaluation, mechanical strength, drug loading (%) and Fourier transform infrared spectroscopy (FTIR) etc. The skin penetration study was performed by using pig ear skin and results were captured through confocal microscopy. Ex-vivo release study and pharmacokinetic evaluation were also performed.
Results: Sharp needle tips with a height of 600µm and a base of 200µm were confirmed through microscopic examination. Optimized formulation (SRF-6) exhibited loading of 92.11% doxazosin mesylate with appreciable strength up to 1.94N force. Ex-vivo release studies revealed 87.24% release within 48 hours. Moreover, the pharmacokinetic parameters in case of optimized patch formulation (SRF-6) were markedly improved i.e. MRT (19.46 h), AUC (57.12 μg.h /mL), Cmax (2.16 µg /mL), tmax (10.10 h) and t1/2 (6.32 h) as compared to commercially available tablet. Biocompatibility of the developed patches was validated from skin irritation studies.
Conclusion: Results confirmed the successful fabrication of microneedle patch having sufficient strength and effective penetration ability into the skin to ensure controlled release of incorporated drug for the intended duration. It can be employed as an efficient carrier system for other therapeutics those are prone to bioavailability issues due to first pass effect after their oral administration.
Download the full article as PDF here: Sustained release microneedle patch for pronounced systemic delivery of doxazosin mesylate
Materials
Chitosan low molecular weight (50 000-190 000 Da), Polyvinyl alcohol (99%) hydrolyzed (85 000-124 000) and acetic acid were procured from Sigma Aldrich (Germany). Doxazosin mesylate was generously gifted by Wilshire Laboratories (PVT), Pakistan. Silicon mold (array size = 10×10, height = 600µm and pitch = 500µm) was purchased from Micropoint technology, Singapore. Distilled water was taken from research laboratory of Faculty of Pharmacy, The University of Lahore.
Imran Anwar, Nadiah Zafar, Asif Mahmood, Zulcaif, Riffat Latif, Sustained release microneedle patch for pronounced systemic delivery of doxazosin mesylate, Anwar et al., BioImpacts. 2025;15:30257, doi: 10.34172/bi.30257, https://bi.tbzmed.ac.ir/
See our next webinar:
“Controlled Release for Nutraceuticals“
Date: 10th of September, Time: 5:00 PM (Amsterdam, Berlin)
![Webinar Controlled Release for Nutraceuticals](https://www.pharmaexcipients.com/wp-content/uploads/2024/08/Webinar-Controlled-Release-for-Nutraceuticals-300x169.jpg)